Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial
GLP-1 receptor agonists and nicotine use: Emerging mechanisms and implications
STEP 1 (Wilding et al., 2021, New England Journal of Medicine) enrolled 1,961 participants and demonstrated a mean body weight reduction of 14.9% at 68 weeks with 2.4mg subcutaneous semaglutide, the first pharmacological intervention to produce weight loss of this magnitude in a Phase 3 trial, establishing a new efficacy benchmark that became the comparison standard for all subsequent metabolic compounds including Tirzepatide and Retatrutide
Oct 2013;3(10):776-779
US$ 22.02
US$ 23.98
US$ 28.09
US$ 28.81
US$ 27.76
US$ 24.50
US$ 20.30
